SBI Securities
ELVN icon

SBI Securities’s Enliven Therapeutics ELVN Stock Holding History

SBI Securities’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.24K Sell
27
-5
-16% -$272 ﹤0.01% 2779
2026
Q2 		$1.62K Buy
32
+7
+28% +$297 ﹤0.01% 2631
2026
Q1 		$980 Sell
25
-12
-32% -$332 ﹤0.01% 2661
2025
Q4 		$570 Sell
37
-1
-3% -$20 ﹤0.01% 2822
2025
Q3 		$778 Buy
38
+1
+3% +$20 ﹤0.01% 2797
2025
Q2 		$742 Hold
37
– – ﹤0.01% 2805
2025
Q1 		$728 Hold
37
– – ﹤0.01% 2723
2024
Q4 		$833 Buy
+37
New +$959 ﹤0.01% 2690

Other funds holding ELVN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Highland Capital Management (Tennessee)
Highland Capital Management (Tennessee) Memphis, Tennessee $2.19B AUM 46.65% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

SBI Securities's ELVN Position: Q3 2026 in Review

SBI Securities reduced its Enliven Therapeutics (ELVN) stake by 16% in Q3 2026, selling an estimated $272 and leaving 27 shares worth $1.24K. The position accounts for ﹤0.01% of the portfolio, ranked #2779.

SBI Securities first reported a position in ELVN in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.62K in Q2 2026. 20 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • SBI Securities held 27 shares of Enliven Therapeutics worth $1.24K as of Q3 2026.
  • SBI Securities sold 5 Enliven Therapeutics shares in Q3 2026, an estimated $272.
  • Enliven Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #2779 holding.
  • SBI Securities first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • SBI Securities's Enliven Therapeutics position peaked at $1.62K in Q2 2026.
  • 20 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.